Drug Trial Radar · NCT01950819
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
Last checked: Nov 19, 2026Latest source record: Jan 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,037
Actual
Start
Dec 3, 2013
Primary completion
Feb 1, 2017
Study completion Jan 17, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.
Conditions
- End Stage Renal Disease (ESRD)
- Chronic Kidney Disease (CKD)
- Hemodialysis
- Renal Replacement Therapy
- Renal Transplantation
Interventions
Induction therapyBiological
All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
CorticosteroidsDrug
All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
EVR+rCNIDrug
Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
MPA+sCNIDrug
Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2.Time frame: Month 12 is Primary, Month 24 secondary
Locations
184 sites in 42 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Loma Linda, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Burlington, Massachusetts
Novartis Investigative Site
Ann Arbor, Michigan
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Livingston, New Jersey
Novartis Investigative Site
Buffalo, New York
Novartis Investigative Site
The Bronx, New York
Novartis Investigative Site
Chapel Hill, North Carolina
Novartis Investigative Site
Durham, North Carolina
Novartis Investigative Site
Winston-Salem, North Carolina
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Harrisburg, Pennsylvania
Novartis Investigative Site
Providence, Rhode Island
Novartis Investigative Site
Charleston, South Carolina
Novartis Investigative Site
Nashville, Tennessee
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Fort Worth, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Salt Lake City, Utah
Novartis Investigative Site
Charlottesville, Virginia
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Madison, Wisconsin
Novartis Investigative Site
Milwaukee, Wisconsin
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.